© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 2, 143-147,
January 19, 2000
© 2000 Oxford University Press
REPORTS |
Initial Stages of Tumor Cell-Induced Angiogenesis: Evaluation Via Skin Window Chambers in Rodent Models
Affiliation of authors: Department of Radiation Oncology, Duke University Medical Center, Durham, NC.
Correspondence to: Chuan-Yuan Li, Ph.D., Box 3455, Duke University Medical Center, Durham, NC 27710 (e-mail: cyli{at}radonc.duke.edu).
BACKGROUND: There is a paucity of information about events that follow immediately after tumor cells are triggered to initiate the process of angiogenesis (the formation of new blood vessels). Such information is relevant to the issue of when micrometastases vascularize and has implications for the accessibility of micrometastases to various treatments. In this study, we attempted to monitor events at the initiation of angiogenesis at the earliest possible stage of tumor growth in vivo. METHODS: Two different rodent mammary tumor cell lines, R3230Ac from the Fischer 344 rat and 4T1 from the BALB/c mouse, were stably transfected with a gene that encodes an enhanced version of green fluorescence protein (GFP). GFP-labeled R3230Ac or 4T1 cells (about 20-50 cells) were implanted into dorsal skinfold window chambers of Fischer 344 rats or BALB/c mice, respectively. Tumor angiogenesis was then monitored serially and noninvasively for up to 4 weeks. RESULTS: Clear evidence of modification of the host vasculature was observed when tumor mass reached approximately 60-80 cells, and functional new blood vessels were seen when tumor mass reached roughly 100-300 cells. Individual tumor cells exhibited a chemotaxis-like growth pattern toward the pre-existing host vasculature. When ex-flk1 (a soluble, truncated vascular endothelial cell growth factor receptor protein known to be antiangiogenic) was injected with the tumor cells, the initial angiogenic and tumor growth activities were inhibited considerably, indicating that angiogenesis inhibitors may halt tumor growth even before the onset of angiogenesis. CONCLUSION: Angiogenesis induced by tumor cells after implantation in the host begins at a very early stage, i.e., when the tumor mass contains roughly 100-300 cells. Identification of chemotactic signals that initiate tumor cell migration toward the existing vasculature may provide valuable targets for preventing tumor progression and/or metastases.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Geng, G. Rachakonda, D. J. Morre, D. M. Morre, P. A. Crooks, V. N. Sonar, J. L. R. Roti, B. E. Rogers, S. Greco, F. Ye, et al. Indolyl-quinuclidinols inhibit ENOX activity and endothelial cell morphogenesis while enhancing radiation-mediated control of tumor vasculature FASEB J, September 1, 2009; 23(9): 2986 - 2995. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Sabeh, R. Shimizu-Hirota, and S. J. Weiss Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited J. Cell Biol., April 6, 2009; 185(1): 11 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Chetty, S. S. Lakka, P. Bhoopathi, S. Kunigal, R. Geiss, and J. S. Rao Tissue Inhibitor of Metalloproteinase 3 Suppresses Tumor Angiogenesis in Matrix Metalloproteinase 2-Down-regulated Lung Cancer Cancer Res., June 15, 2008; 68(12): 4736 - 4745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Bullitt, N. U. Lin, J. K. Smith, D. Zeng, E. P. Winer, L. A. Carey, W. Lin, and M. G. Ewend Blood Vessel Morphologic Changes Depicted with MR Angiography during Treatment of Brain Metastases: A Feasibility Study Radiology, December 1, 2007; 245(3): 824 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Fruehauf and F. L. Meyskens Jr. Reactive Oxygen Species: A Breath of Life or Death? Clin. Cancer Res., February 1, 2007; 13(3): 789 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Dome, M. J.C. Hendrix, S. Paku, J. Tovari, and J. Timar Alternative Vascularization Mechanisms in Cancer: Pathology and Therapeutic Implications Am. J. Pathol., January 1, 2007; 170(1): 1 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Gerber, V. Y. Rybalko, C. E. Bigelow, A. A. Lugade, T. H. Foster, J. G. Frelinger, and E. M. Lord Preferential Attachment of Peritoneal Tumor Metastases to Omental Immune Aggregates and Possible Role of a Unique Vascular Microenvironment in Metastatic Survival and Growth Am. J. Pathol., November 1, 2006; 169(5): 1739 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Rofstad, B. Mathiesen, K. Kindem, and K. Galappathi Acidic Extracellular pH Promotes Experimental Metastasis of Human Melanoma Cells in Athymic Nude Mice. Cancer Res., July 1, 2006; 66(13): 6699 - 6707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Bullitt, P.A. Wolthusen, L. Brubaker, W. Lin, D. Zeng, and T. Van Dyke Malignancy-Associated Vessel Tortuosity: A Computer-Assisted, MR Angiographic Study of Choroid Plexus Carcinoma in Genetically Engineered Mice AJNR Am. J. Neuroradiol., March 1, 2006; 27(3): 612 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Brubaker, E. Bullitt, C. Yin, T. Van Dyke, and W. Lin Magnetic Resonance Angiography Visualization of Abnormal Tumor Vasculature in Genetically Engineered Mice Cancer Res., September 15, 2005; 65(18): 8218 - 8223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Cao, C.-Y. Li, B. J. Moeller, D. Yu, Y. Zhao, M. R. Dreher, S. Shan, and M. W. Dewhirst Observation of Incipient Tumor Angiogenesis That Is Independent of Hypoxia and Hypoxia Inducible Factor-1 Activation Cancer Res., July 1, 2005; 65(13): 5498 - 5505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Paris and R. Sesboue Metastasis models: the green fluorescent revolution? Carcinogenesis, December 1, 2004; 25(12): 2285 - 2292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ferrara Vascular Endothelial Growth Factor as a Target for Anticancer Therapy Oncologist, June 1, 2004; 9(suppl_1): 2 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Herbst and A. B. Sandler Non-Small Cell Lung Cancer and Antiangiogenic Therapy: What Can Be Expected of Bevacizumab? Oncologist, June 1, 2004; 9(suppl_1): 19 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Rugo Bevacizumab in the Treatment of Breast Cancer: Rationale and Current Data Oncologist, June 1, 2004; 9(suppl_1): 43 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C.L. Schuh Trials, Tribulations, and Trends in Tumor Modeling in Mice Toxicol Pathol, January 1, 2004; 32(1_suppl): 53 - 66. [Abstract] [PDF]
|
|
|
|
|
|
C. Cuadros, A. L. Dominguez, G. I. Frost, P. Borgstrom, and J. Lustgarten Cooperative Effect between Immunotherapy and Antiangiogenic Therapy Leads to Effective Tumor Rejection in Tolerant Her-2/neu Mice Cancer Res., September 15, 2003; 63(18): 5895 - 5901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Nayha, J. Laitakari, and F. Stenback Stage-Dependent Expression of an Angiogenic Agent and Vascular Organization in Experimental Skin Tumor Development Toxicol Pathol, August 1, 2003; 31(5): 539 - 548. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Nair, D. Boczkowski, B. Moeller, M. Dewhirst, J. Vieweg, and E. Gilboa Synergy between tumor immunotherapy and antiangiogenic therapy Blood, August 1, 2003; 102(3): 964 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. V. N. Lord, J. M. Park, K. Wickramasinghe, S. R. DeMeester, S. Oberg, D. Salonga, J. Singer, J. H. Peters, K. D. Danenberg, T. R. DeMeester, et al. Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus J. Thorac. Cardiovasc. Surg., February 1, 2003; 125(2): 246 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Taylor, L. Osorio, R. Craig, J. A. Raleigh, Z. Ying, D. M. Goldenberg, and R. D. Blumenthal Tumor-specific Regulation of Angiogenic Growth Factors and Their Receptors during Recovery from Cytotoxic Therapy Clin. Cancer Res., April 1, 2002; 8(4): 1213 - 1222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Erlach, J. Podlech, A. Rojan, and M. J. Reddehase Tumor Control in a Model of Bone Marrow Transplantation and Acute Liver-Infiltrating B-Cell Lymphoma: an Unpredicted Novel Function of Cytomegalovirus J. Virol., February 22, 2002; 76(6): 2857 - 2870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Coleman, J. B. Mitchell, and K. Camphausen Tumor Hypoxia: Chicken, Egg, or a Piece of the Farm? J. Clin. Oncol., February 1, 2002; 20(3): 610 - 615. [Full Text] [PDF]
|
|
|
|
|
|
B. Kusters, W. P. J. Leenders, P. Wesseling, D. Smits, K. Verrijp, D. J. Ruiter, J. P. W. Peters, A. J. van der Kogel, and R. M. W. de Waal Vascular Endothelial Growth Factor-A165 Induces Progression of Melanoma Brain Metastases without Induction of Sprouting Angiogenesis Cancer Res., January 1, 2002; 62(2): 341 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Marchand, N. Noiseux, J.-F. Tanguay, and M. G. Sirois Blockade of in vivo VEGF-mediated angiogenesis by antisense gene therapy: role of Flk-1 and Flt-1 receptors Am J Physiol Heart Circ Physiol, January 1, 2002; 282(1): H194 - H204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A R Padhani and M Neeman Challenges for imaging angiogenesis Br. J. Radiol., October 1, 2001; 74(886): 886 - 890. [Full Text] [PDF]
|
|
|
|
|
|
S. Shan, A. C. Lockhart, W. Y. Saito, A. M. Knapp, K. R. Laderoute, and M. W. Dewhirst The Novel Tubulin-binding Drug BTO-956 Inhibits R3230Ac Mammary Carcinoma Growth and Angiogenesis in Fischer 344 Rats Clin. Cancer Res., August 1, 2001; 7(8): 2590 - 2596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Guba, G. Cernaianu, G. Koehl, E. K. Geissler, K.-W. Jauch, M. Anthuber, W. Falk, and M. Steinbauer A Primary Tumor Promotes Dormancy of Solitary Tumor Cells before Inhibiting Angiogenesis Cancer Res., July 1, 2001; 61(14): 5575 - 5579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Konopka, J. E. Barker, T. L. Bamford, E. Guida, R. L. Anderson, and A. G. Stewart Nitric Oxide Synthase II Gene Disruption: Implications for Tumor Growth and Vascular Endothelial Growth Factor Production Cancer Res., April 1, 2001; 61(7): 3182 - 3187. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Yang, E. Baranov, X.-M. Li, J. W. Wang, P. Jiang, L. Li, A. R. Moossa, S. Penman, and R. M. Hoffman Whole-body and intravital optical imaging of angiogenesis in orthotopically implanted tumors PNAS, February 27, 2001; 98(5): 2616 - 2621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Hoffman Re: Initial Stages of Tumor Cell-Induced Angiogenesis: Evaluation Via Skin Window Chambers in Rodent Models J Natl Cancer Inst, September 6, 2000; 92(17): 1445 - 1446. [Full Text] [PDF]
|
|
|
|
|
|
C.-Y. Li, S. Shan, Q. Huang, and M. W. Dewhirst RESPONSE: Re: Initial Stages of Tumor Cell-Induced Angiogenesis: Evaluation Via Skin Window Chambers in Rodent Models J Natl Cancer Inst, September 6, 2000; 92(17): 1445a - 1446a. [Full Text] [PDF]
|
|
|
|
|
|
E. K. Rofstad and E. F. Halsør Vascular Endothelial Growth Factor, Interleukin 8, Platelet-derived Endothelial Cell Growth Factor, and Basic Fibroblast Growth Factor Promote Angiogenesis and Metastasis in Human Melanoma Xenografts Cancer Res., September 1, 2000; 60(17): 4932 - 4938. [Abstract] [Full Text]
|
|
|
|
|
|
J. Folkman Incipient Angiogenesis J Natl Cancer Inst, January 19, 2000; 92(2): 94 - 95. [Full Text] [PDF]
|
|
|
|
|
|
K. Mishima, A. P. Mazar, A. Gown, M. Skelly, X.-D. Ji, X.-D. Wang, T. R. Jones, W. K. Cavenee, and H.-J. S. Huang A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin PNAS, July 18, 2000; 97(15): 8484 - 8489. [Abstract] [Full Text] [PDF]
|
|